Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Achilles Therapeutics ( (ACHL) ) just unveiled an update.
Achilles Therapeutics has sold its technology assets, including data and samples from the TRACERx study and its Material Acquisition Platform (MAP), to AstraZeneca for $12 million. This transaction marks the conclusion of a strategic review by Achilles, which will now implement further cost-reduction measures, including staff cuts and board resizing, as it adapts its business strategy in compliance with Nasdaq and SEC regulations.
More about Achilles Therapeutics
Achilles Therapeutics is a clinical-stage biopharmaceutical company that develops AI-powered precision T cell therapies aimed at targeting clonal neoantigens, which are unique protein markers expressed on cancer cells. The company uses DNA sequencing data and its proprietary PELEUS bioinformatics platform to identify patient-specific clonal neoantigens, enabling the development of targeted product candidates.
YTD Price Performance: 28.09%
Average Trading Volume: 157,516
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $46.84M
Find detailed analytics on ACHL stock on TipRanks’ Stock Analysis page.
